Jump to content

PRINCE: A phase III study of intermittent chemotherapy

Paul Edwards

Recommended Posts

We are all familiar with the concept of intermittent ADT as opposed to continuous ADT.


Now researchers are investigating the concept of intermittent chemotherapy as opposed to continuous chemotherapy.  If certain criteria are met, there will a break in the chemotherapy treatment and the patient will have a “drug holiday”.


In theory intermittent chemotherapy may serve 2 purposes.


First, with less constant exposure to the drug, this may potentially delay the development of taxane-refractory disease.


Second, breaks in therapy or “drug holidays” may improve the quality of life for patients, allowing them to recover from the cumulative toxicity of chemotherapy during these “drug holidays.”  Resolution of drug side effects may also allow taxane therapy to be prolonged, which could also improve outcomes.


It is interesting to see that one of the abstracts for the 2016 ASCO (American Society of Clinical Oncologists) meeting in Chicago next week is about “PRINCE: A phase III study comparing intermittent docetaxel therapy versus continuous docetaxel therapy in patients with castration-resistant prostate cancer”.


PRINCE which was a study conducted by German researchers found that:

“The intermittent docetaxel chemotherapy was non-inferior to a continuous therapy in one-year survival. It was well tolerated and may present a treatment option for patients with CRPC”.


Reference: http://abstract.asco.org/176/AbstView_176_170886.html

Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...